An ECRI report identifies reasons medications have been under-utilized and urges action to help combat America’s obesity epidemic.

Last year CDER approved 37 new drugs never before approved or marketed in the U.S., known as “novel” drugs, as noted in its annual New Drug Therapy Approvals report. The agency also approved drugs in new settings, such as for new uses and patient populations.

The U.S. Food and Drug Administration approved Eisai Co Ltd’s and Biogen Inc’s Alzheimer’s drug lecanemab for patients in the earliest stages of the mind-wasting disease, the agency said on Friday.

A letter published Wednesday in the NEJM links a stroke patient’s death to lecanemab. Eisai investigators respond.

The announcement comes as the company awaits the FDA’s decision for Biogen and Japanese partner Eisai Co’s Alzheimer’s drug lecanemab.

After setting record-high U.S. prices in the first half of 2022, drugmakers continued to launch medicines at high prices in the second half, a Reuters analysis has found, highlighting their power despite new legislation to lower costs for older prescription products.

The agency’s top five represent an eclectic mix of cancer, cardiovascular and rare disease drugs.

It is the first FDA-approved monoclonal antibody to treat COVID-19, according to the company.

Philips said the latest tests indicated that exposure to particulate matter emissions from degraded foam in DreamStation devices was “unlikely to result in an appreciable harm to health in patients”, provided the machines had not been treated with ozone-based cleansing products.

Entrada Therapeutics said it received a clinical hold notice from the regulatory agency but no reason was provided. “We are eager to resolve this hold and continue down the treatment development pathway,” President and CEO Dipal Doshi said.